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A novel PEG–haloperidol conjugate with a
non-degradable linker shows the feasibility
of using polymer–drug conjugates in a
non-prodrug fashion
Felicity Heath,a Amy Newman,a Chiara Clementi,b Gianfranco Pasut,b Hong Lin,a
Gary J. Stephens,a Benjamin J. Whalley,a Helen M. I. Osborna and Francesca Greco*a
A PEG–haloperidol conjugate containing a non-biodegradable
linker was synthesised. Incubation with rat plasma demonstrated
excellent linker stability, and competition radioligand binding
assays demonstrated retained binding to the D2-receptor. In silico
studies predicted that the conjugate will not cross the blood–brain
barrier (BBB), thus potentially restricting haloperidol action to one
side of the BBB.
1. Introduction
Many drugs display an unfavourable body distribution, which
results in unwanted exposure of healthy tissues to the drug.
One such case applies to drugs that have their desired thera-
peutic target in the central nervous system (CNS) but display
unwanted eﬀects due to their peripheral action. An example is
L-DOPA, used in the treatment of Parkinson’s disease, which
can cause nausea and vomiting as a result of stimulation of
the peripheral dopamine receptors by its metabolite dopa-
mine.1,2 The opposite is also true, in that some drugs acting in
the peripheral tissues display unwanted eﬀects centrally. First
generation anti-histamines that are able to cross the blood
brain barrier (BBB) are widely known to cause side eﬀects of
drowsiness.3,4 In both scenarios, preventing drug permeation
across the BBB would eﬀectively localise drug action to a
single compartment: periphery following peripheral adminis-
tration, or central, following central administration. Many
factors aﬀect drug permeability across the BBB (e.g. lipophili-
city and hydrogen bonding capacity), but size is known to play
a particularly crucial role.5–7 Conjugation of a small, BBB-pene-
trating drug molecule to a polymer could restrict its transit
across this barrier, thus removing any undesired eﬀects in
either compartment. Indeed, Satchi-Fainaro et al. have demon-
strated that conjugation of an anti-tumour agent, TNP-470, to
an HPMA-copolymer resulted in a significant reduction in
neurotoxicity compared to the free drug. These findings suggested
that conjugation to the polymer prevented its BBB passage.8
However, the system was still not ideal as the drug (TNP-470)
was conjugated via a degradable linker (a peptidyl linker). As
such, this conjugate still had the potential for drug-related
toxicity once the drug is released. More recently, a PEGylated
opioid antagonist (Movantik™) has been marketed as a per-
ipherally-acting opioid antagonist for the treatment of opioid-
induced constipation.9 Further, Kopecek and colleagues have
proposed “drug free” polymer–drug conjugates, in which the
polymer is an active agent per se’.10,11
The concept of restricting the action of a drug selectively to
the periphery or to the CNS, by its covalent conjugation to a
polymer, is scientifically appealing, but for this strategy to
work two conditions must be met. First, the polymer must be
able to prevent the drug from crossing the BBB. Second, the
polymer conjugated drug must retain (at least partially) its bio-
logical activity. Meeting the first condition is very straight-
forward as it is well known that size is a key modulator of BBB
permeation.12 The second condition is much more challenging
and requires careful selection of an appropriate ligand.
This study explores, for the first time, application of this
strategy to the dopaminergic system. In particular, we propose
a polymer–drug conjugate that will: (a) be stable in biological
fluids, thus preventing unwanted drug release from the conju-
gate, (b) retain some ability to modulate the dopaminergic
system, (c) have a size compatible with what has been reported
to be BBB non-permeable. To explore this hypothesis, the
D2 receptor antagonist, haloperidol (Fig. 1) was selected for
conjugation to a linear bifunctional PEG polymer.
This ligand presents a series of characteristics rendering it
suitable for the proposed application, namely: (i) it is an anta-
gonist of the chosen system (dopaminergic); (ii) as a free drug,
it is able to cross the BBB; (iii) the hydroxyl group is a suitable
point for conjugation; (iv) importantly, previous studies
showing conjugation to aﬃnity columns had shown an
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indication of ability to maintain its binding capacity to the D2
receptor after conjugation to sepharose solid supports as
aﬃnity column ligand.13
The system proposed in this study diﬀers dramatically from
most of the polymer-small-drug conjugates being developed,
as the latter typically act as prodrugs and generally require a
biodegradable bond or linker between polymer and drug to
exert their action.14–18 Conversely, here we suggest a non
degradable polymer–drug conjugate, in which the size of the
polymer matches that needed to prevent BBB crossing, and in
which the conjugation has been carried out at a point that
allows (at least partial) retention of activity. The pharmacologi-
cal target of the conjugate presented in this work (the dopa-
mine D2 receptor) has the advantage of being expressed both
centrally19–21 and peripherally,21–24 and also of being easily
accessible to polymer–drug conjugates as a result of its
location, for instance, on the plasma membrane of neuronal
cells.
In this paper we report the synthesis, characterisation and
in vitro biological assessment of a polymer–haloperidol conju-
gate designed to inhibit passage across the BBB. First, we
report PEGylation of the chosen drug. PEG was chosen as the
polymeric component due to its favourable properties such as:
prolonged residence in the body, decreased metabolic degra-
dation of the attached drug and improved solubility.25,26 Then,
stability of the bond between the polymer and the drug was
assessed in vitro using rat plasma. The ability of the conjugate
to bind to D2 receptors was determined using radioligand
binding assays. Finally, a theoretical model was employed
to investigate the likelihood of PEG conjugation restricting
the passage of haloperidol across the BBB. As such, this study
can be considered as the first stage in determining the feasi-
bility of the polymer–haloperidol conjugate for selective
delivery to the central or peripheral system, after which it will
be pertinent to conclude whether in vivo studies would be
warranted.
2. Results and discussion
2.1. Synthesis and characterisation
To synthesise the PEG–haloperidol conjugate, direct conju-
gation of haloperidol to PEG via its tertiary hydroxyl group was
initially attempted using the methane sulfonate ester of bis-
hydroxy PEG. However, no reaction was observed with haloper-
idol, presumably due to the sterically hindered nature of the
hydroxyl group. To aid conjugation of haloperidol to PEG, an
ethylenediamine linker was attached to the hydroxyl group
through a carbamate bond, introducing an accessible amine
handle for subsequent conjugation to a polymer (Fig. 2).
The conjugation of haloperidol to a drug delivery carrier
has not been extensively explored within the literature. Most
Fig. 1 Chemical structure of the D2 receptor antagonist haloperidol.
Fig. 2 Panel A: Synthetic scheme of haloperidol-amino ethyl carbamate (haloperidol-AEC) (I), and PEG–haloperidol (III), Panel B: 1H-NMR spectrum
of PEG–haloperidol, Panel C: C18 HPLC chromatogram of PEG–haloperidol (tR = 17.2 min) and free haloperidol (tR = 16.1), Panel D: Characterisation
of PEG–haloperidol.
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examples of derivatisation of haloperidol at the hydroxyl group
involve the formation of an ester bond.27–30 This is likely to be
susceptible to degradation by esterases in vivo31 and hence
would not be suitable for this study. Therefore we examined
a carbamate linkage which was anticipated to be more
stable.31,32
A method was developed for synthesis of the haloperidol–
polymer conjugate that involved activation of haloperidol with
p-nitrophenyl chloroformate, prior to reaction with ethylene-
diamine to give haloperidol amino-ethyl carbamate (haloperi-
dol-AEC) (Fig. 2A). An excess of ethylene diamine was used to
limit coupling of haloperidol to both ends of the linker.
This reaction produced the target compound in a good yield
of 49%.
The subsequent conjugation strategy involved reaction of
the derivatised ligand with bis-carboxy PEG through the use of
widely exploited carbodiimide coupling chemistry (Fig. 2).
PEG–haloperidol was successfully synthesised, as verified by
1H and 13C NMR spectroscopic analysis, which showed evi-
dence of the characteristic peaks of haloperidol and PEG
(Fig. 2B). Also, MALDI TOF analysis showed a shift in the mass
distribution of the conjugates to higher masses compared to
unmodified PEG, mirroring the degree of ligand loading
(Fig. 2D).
Total haloperidol content was determined using 1H NMR
spectroscopic analysis. For the NMR analysis, ratios were deter-
mined for the peak areas representing the aromatic protons of
haloperidol between 8.2–6 ppm and the peak areas of PEG
protons from 3.8–3.4 ppm (Fig. 2B). PEG–haloperidol showed
a loading of 6.1% w/w. The polymer conjugate was purified by
precipitation in diethyl ether, followed by dialysis against
water which gave a low residual free drug content of less than
0.8% w/w (of total drug), determined by RP-HPLC.
2.2. Stability of conjugate in plasma
For our proposed strategy to be eﬀective, formation of a stable
bond between the drug and the polymer is essential, as a bio-
degradable bond would result in drug release and subsequent
crossing of the BBB, thus defeating the purpose of conju-
gation. Conjugate stability was tested in vitro upon incubation
with rat plasma in order to probe stability under physiological
conditions. Stability was assessed using HPLC to measure the
amount of haloperidol released after incubation for varying
lengths of time. Pleasingly, the conjugate proved stable when
challenged with biological fluids. In particular PEG–haloperi-
dol showed release of only 1% free haloperidol at 72 h, increas-
ing up to only 2% after 1 week (Fig. 3). Interestingly, it was
observed that the point of cleavage was at the carbamate bond
in the haloperidol-AEC structure, shown by RP-HPLC with the
release corresponding to free haloperidol, rather than free
haloperidol-AEC (data not shown).
2.3. Assessment of the binding to the dopamine D2 receptor
in vitro
The ability of the ligands to maintain some binding to D2
receptors after conjugation to PEG was crucial for our hypoth-
esis to be viable, and hence worthy of future in vivo studies.
The vast majority of polymer–drug conjugates rely on drug
release to trigger biological eﬀects. Therefore, it was essential
to determine whether aﬃnity of the conjugate for the D2 recep-
tor was retained, and this was assessed by quantifying PEG–
haloperidol’s ability to displace the [3H] spiperone agonist
binding in membrane preparations from Chinese hamster
ovary (CHO) cells stably expressing D2 receptors. Dopamine
was used as a positive control (pKi = 6.22 ± 0.09, n = 3) and
PEG as a negative control (Fig. 4a).
Fig. 3 Stability of PEG–haloperidol conjugate on incubation with rat
plasma. Data expressed as mean ± SEM (n = 3). Error bars hidden by the
symbols when not visible.
Fig. 4 Binding curves for compounds competing with [3H] spiperone in
D2 receptors from CHO cells: (a) PEG, negative control and dopamine,
positive control, (b) PEG–haloperidol and free haloperidol. Data
expressed as the mean ± SEM, (n = 3). pKi values were derived from data
ﬁtted to a single-binding site model.
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PEG–haloperidol was able to retain aﬃnity for the D2 recep-
tor, albeit with a lower pKi (6.92 ± 0.06, n = 3) compared to free
haloperidol (8.05 ± 0.19, n = 3) (Fig. 4b). This reduction is in
line with a previous report measuring BSA-conjugated halo-
peridol binding to the D2 receptor13 and as the binding is still
sub-micromolar, it indicates potential for future applications.
2.4. Theoretical modelling to assess the ability of PEG
conjugation to restrict passage of D2 receptor ligands across
the BBB
It has long been known that large molecules are generally
unable to cross the BBB. In particular, a MW of 400–600 is nor-
mally considered the upper limit for crossing the BBB.33–35 As
the conjugate described in this study has a MW >than 6000 g
mol−1 and is therefore well above this threshold, a gross
restriction in its passive diﬀusion across the BBB is antici-
pated. However, to support this further, theoretical calcu-
lations were carried out using a model, proposed by Fu et al.36
(see section 4.10). The model predicts a log value of the ratio
of concentration of compound in the brain : blood and has
been employed in order to examine the hypothesis proposed
in this paper; that the conjugation of haloperidol to PEG 6000
will inhibit its ability to cross the BBB.
The model predicts that haloperidol would be able to cross
the BBB, which is well known and supported by experimental
evidence.37 However, conjugation of haloperidol to PEG leads
to a large reduction in the blood to brain concentration ratio
predicted by the model (log BB shifting from 0.11 for haloperi-
dol to −484.32 for the conjugate, Table 1), which means an
overwhelming bias towards localisation within the blood.
It should be noted that the model used by Fu et al. was
derived from a training set of 78 small molecule compounds
using stepwise multiple regression analysis. The leave one out
procedure was used to cross validate the model. While the
model was developed from a range of small molecules, Fu
et al. did not apply any restrictions with respect to the validity
of their system for larger molecules, and indeed, molecular
weight is one of the key parameters in their equation.
Conversely, Fu et al. highlight that their equation only
accounts for passive diﬀusion and that any compounds that
are aﬀected by P-glycoprotein eﬄux transporter are likely to be
less well predicted. However, these limitations are unlikely to
aﬀect the predictions obtained for our system because halo-
peridol itself is known to be an inhibitor and not a substrate
for P-glycoprotein eﬄux38,39 and PEG is thought to also have
some inhibitory properties on P-glycoprotein.40
These theoretical predictions highlight the significant
change in properties (with respect to size, hydrogen bond
forming potential and lipophilicity) conferred to haloperidol
upon conjugation to PEG. The theoretical modelling indicates
that the PEG bound haloperidol would substantially restrict
the passage of the haloperidol across the BBB.
Stimulation of dopamine receptors present in either the
CNS or the periphery can result in a diverse spectrum of
eﬀects depending on the location of the receptor making this
system an ideal model for the proposed strategy. For example,
in the brain, dopamine plays a role in the control of move-
ment and behaviour,41–44 whereas, in the periphery, dopa-
mine can aﬀect the control of cardiovascular and renal func-
tion and hormone secretion.21,22,24,45 The ability to de-couple
peripheral from central eﬀects, through the proposed size
exclusion mediated system, is certainly a powerful tool for
investigative purposes. In addition, a conjugate able to elicit
selective central or peripheral responses could potentially be
used in in vivo models to mimic pathological conditions
characterised by a selectively increased or decreased dopa-
minergic tone.
3. Conclusions
In this paper we present for the first time the synthesis and
in vitro biological investigation of a PEG–haloperidol conju-
gate for use as an agent per se rather than in the convention-
al pro-drug fashion. The challenge of this study was to gene-
rate a stable derivative that would be expected to be BBB
non-permeable whilst retaining some aﬃnity for the target
receptor.
A PEG–haloperidol conjugate was successfully synthesised
and characterised. The conjugate displayed excellent stability,
upon challenge with simulated physiological conditions.
Radioligand binding studies showed that PEG–haloperidol was
still able to bind to the D2 receptor albeit with a lower aﬃnity
compared to the free ligand. Theoretical modelling suggested
that the conjugate would dramatically restrict the passage of
haloperidol across the BBB. Taken together these results
indicate that the PEG–haloperidol conjugate warrants future
in vivo investigation, in the context of developing a system able
to selectively (peripherally or centrally) modulate the dopamin-
ergic system.
4. Experimental section
4.1. Materials
Alpha, omega-bis-carboxy PEG (≈6000 Da) was purchased from
Iris Biotech GmbH, Germany. All other chemicals and
anhydrous solvents were purchased from Sigma Aldrich, apart
from extra dry chloroform and sodium trifluoroacetate for
MALDI-TOF-MS analysis which were purchased from Acros
Organics. Other solvents were supplied by Fisher Scientific
and deuterated solvents for NMR analysis were from
Table 1 Calculated log BB values for haloperidol and PEG–haloperidol
conjugate
Compound Mw npol log BB
a
Haloperidol 375.9 5 0.11
PEG–haloperidol 7108 156 −484.32
a Calculated using eqn (1).
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Cambridge Isotope Laboratories. Rat plasma was obtained
from whole blood taken from male Wistar rats, P > 21 (Harlan,
UK), which was subsequently spun at 3, 500 rpm for 10 min
and the plasma removed. Animals were humanely dispatched
by a Schedule 1 (Animals Scientific Procedures Act, 1986)
method prior to blood collection.
4.2. Instrumentation and software
1H NMR and 13C NMR spectra were obtained using Bruker
spectrometers operating at either 700 MHz or 400 MHz and
processed using Topspin software. Spectra were analysed using
ACD/SpecManager software Version 12.01. HPLC analysis was
performed on a Hewlett Packard series 1100 instrument
equipped with an ACE C18 reverse phase column (300 µm,
250 × 4.6 mm) (Hichrom, UK). MALDI-TOF spectra were
obtained on a Bruker Ultraflex MALDI-TOF/TOF mass
spectrometer. The MALDI data were processed using Bruker
Daltonics, FlexAnalysis version 3.0 software. Radioligand com-
petition binding assay results were analysed using GraphPad
Prism software, version 5.04.
4.3. Modification of haloperidol to contain an amine handle
Haloperidol (150 mg, 0.4 mmol) was dissolved in anhydrous
CH2Cl2 (10 mL). To the solution, p-nitrophenyl chloroformate
(160 mg, 0.8 mmol) and triethylamine (139 µL, 1.0 mmol)
were added. The reaction was stirred for one hour at room
temperature and then added drop wise to a solution of ethyl-
enediamine (267 µL, 4 mmol) in DMF (20 mL). The reaction
was stirred overnight and monitored by RP-HPLC. The halo-
peridol-amino ethyl carbamate (haloperidol-AEC) product was
purified by washing with 0.1 M sodium hydrocarbonate
(3 × 200 mL), followed by chromatography on a SiO2 column
(30 × 2.5 cm) eluted with a chloroform–methanol mixture
(90 : 10 to only methanol) and determined by TLC analysis
(yield 49%). Successful synthesis was confirmed using HPLC
and 1H and 13C NMR spectroscopic analysis. The introduction
of free amine groups was verified using the 2,4,6-trintiro-
benzenesulfonic acid assay.46
1H NMR (CDCl3, 400 MHz): 8.04 (1H, s, CvO(NH)CH2),
7.93 (2H, dd, Jab = 9.0 Hz, JaF = 5.5 Hz, Ar–F), 7.22 (4H, dd, J =
9.5 Hz, J = 9.0 Hz, Ar–Cl), 7.05–7.03 (2H, m, Ar–F), 5.20–5.10
(2H, m, NH2), 3.34–3.26 (2H, m, OCvO(NH)CH2CH2NH2),
3.22–3.14 (2H, m, OCvO(NH)CH2CH2NH2), 2.94 (2H, t,
J = 7.5 Hz, –CvO(CH2)CH2CH2–), 2.84–2.75 (2H, m, –N <
(CHHCH2)2 > C), 2.5–2.43 (2H, m, CH2–N < (CH2CH2)2 > C),
2.41–2.31 (2H, m, –N < (CHHCH2)2 > C), 2.01–1.87 (4H, m,
–N < (CH2CH2)2 > C). 13C NMR (CDCl3, 100 MHz) 198.38
(F–Ar–CvOCH2–), 165.64 (d, JFC = 250 Hz, Ar–F, (ipso-C))
154.97 (O–CvO(NH)–), 143.8 (Ar–Cl, (para-C)), 133.67 (d, JFC =
3 Hz Ar–F (para-C)), 132.92 (Ar–Cl, (ipso-C)), 130.65 (d, JFC =
10.5 Hz, Ar–F (meta-C)), 128.5 (Ar–Cl (meta-C)), 125.99 (Ar–Cl
(ortho-C)), 115.62 (d, JFC = 22.0 Hz, Ar–F (ortho-C)), 78.84
((CH2)2 > C < (O–)(Ar–Cl)), 57.67 (CH2CH2N<), 49.27 (N <
(CH2)2 (CH2)2), 43.33 (CH2CH2NH2), 41.75 (NHCH2CH2),
36.20 (CvO(CH2)CH2), 35.92 ((CH2)2 (CH2)2 > C<), 21.9
(CH2CH2CH2).
4.4. Activation of bis-carboxy PEG with
N-hydroxysuccinimide
Bis-carboxy-PEG (Mw ∼ 6000, 1 g, 167 µmol) was dissolved
in anhydrous CH2Cl2 (∼20 mL). To this was added,
N-hydroxysuccinimide (NHS) (3 equiv., 64 mg, 555 µmol),
followed by N,N′-dicyclohexylcarbodiimide (DCC) (6.45 equiv.,
0.222 g, 1.1 mmol). The reaction was left stirring for 5 hours.
Within 30 minutes the reaction had turned cloudy. The reac-
tion mixture was filtered through celite and the filtrate directly
added into cold diethyl ether (500 mL) with vigorous stirring.
This precipitated material was left on ice for 1 h, before filter-
ing to recover the white precipitate. The recovered solid was
dried under vacuum. The degree of end group activation of the
polymer was determined indirectly by measuring the amount
of free amine groups remaining after reaction of the activated
PEG with an equimolar quantity of the di-peptide gly–gly in
borate buﬀer at pH 8, using the colorimetric 2,4,6-trinitro-
benzene sulfonic acid assay.46
4.5. Synthesis of PEG–haloperidol conjugate
Haloperidol-AEC (7 equiv., 64 mg, 139 µmol) was dissolved in
anhydrous CHCl3 (5 mL) and anhydrous N,N-diisopropyl-
ethylamine (DIPEA) (25 µL, 139 µmol, 7 equiv.) was added.
NHS-activated PEG (Mw 6308 equiv., 112 mg, 17 µmol) was
added portion-wise and the reaction then stirred under a nitro-
gen atmosphere, protected from light for 3 days. The reaction
was monitored in the early stages using RP-HPLC. The solvent
was then evaporated in vacuo, to leave ∼3 mL, before adding
this dropwise to ice cold diethyl ether (200 mL). The solution
was kept on ice for one hour before filtering to recover the fine
white precipitate. The solid was then dried in vacuo before dis-
solving in water (∼10 mL). This was dialysed against distilled
water, using a regenerated cellulose membrane of MWCO 1000
Da, with 3 changes of water over a 24 hour period. The product
was freeze dried and subjected to RP-HPLC to determine
purity. A small amount of free haloperidol-AEC was still
present, which resulted in the product needing further purifi-
cation. PEG–haloperidol-AEC was re-dissolved in around 4 mL
of methanol and loaded on to a LH-20 sephadex column. The
column was run using 100% methanol and fractions contain-
ing UV active material (as determined via TLC analysis) were
analysed by HPLC. Fractions containing the conjugate were
combined, and the methanol removed in vacuo. The residue
was dissolved in distilled water and freeze dried once again
(yield, 24%). The conjugate was characterised by 1H and
13C-NMR spectroscopic analysis, MALDI-TOF mass spec-
trometry, RP-HPLC and UV absorbance spectrophotometry.
The amount of haloperidol bound to the polymer and free
drug was determined using 1H NMR spectroscopic analysis
and RP-HPLC.
1H NMR (CDCl3, 500 MHz): 8.03 (dd, haloperidol-AEC, Jab =
7.5 Hz, JaF = 4.5 Hz, Ar–F), 7.33–7.29 (m, haloperidol, Ar–Cl),
7.15–7.12 (m, haloperidol, Ar–F), 3.8–3.4 (m, PEG, CH2CH2O),
3.33–3.29 (m, haloperidol-AEC NHCH2CH2NH), 3.21–3.15
(m, haloperidol-AEC), 2.60–2.50 (m, PEG and haloperidol-AEC),
Communication Polymer Chemistry
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2.25–2.00 (m, haloperidol-AEC). 13C NMR (CDCl3, 125 MHz)
173.16 (PEG, –CH2CvO(OH)), 172.93 (PEG, NHCvO(CH2)–),
165.82 (d, JFC = 253.0 Hz, haloperidol-AEC, Ar–F, (ipso-C)),
154.92 (haloperidol-AEC, –OCvO(NH)–), 133.25 (haloperidol-
AEC, Ar–Cl, (ipso-C)), 130.76 (d, JFC = 9.5 Hz, haloperidol-AEC,
Ar–F (meta-C)), 128.64 (haloperidol-AEC, Ar–Cl (meta-C)),
126.04 (haloperidol-AEC, Ar–Cl (ortho-C)), 115.75 (haloperidol-
AEC, d, JFC = 20.5 Hz, Ar–F (ortho-C)), 72.57 (haloperidol-AEC,
(CH2)2 > C < (O)(Ar–Cl)), 70.55 (PEG, –(OCH2CH2)n), 56.83
(haloperidol-AEC, (CH2CH2N<)), 48.62 (haloperidol-AEC, N <
(CH2)2 (CH2)2), 40.23 (PEG, NHCH2CH2 (OCH2CH2)n), 39.6
(haloperidol-AEC, (CH2)2(CH2)2 > C<), 39.24 (haloperidol-AEC,-
NHCH2CH2NH–), 39.24 (haloperidol-AEC, –NHCH2CH2NH–),
36.09 (haloperidol-AEC, CvO(CH2)CH2), 32.13 (PEG,
CvOCH2CH2CvO), 31.95 (PEG, CvOCH2CH2CvO(OH)),
29.69 (PEG, –CH2CH2CvO(OH)), 28.13 (haloperidol-AEC,
CH2CH2CH2).
4.6. RP-HPLC analysis of PEG–haloperidol
PEG–haloperidol was analysed using RP-HPLC with a C18
(300 µm, 250 × 4.6 mm) column at a flow rate of 1 mL min−1.
The eluent was: A; acetonitrile and B; water containing 0.25%
acetic acid. The protocol for analysis of PEG–haloperidol com-
prised UV absorbance detection at 254 nm, using a gradient of
10% A increasing to 70% A over 25 minutes, returning to
10% A in the following 10 minutes with a total run time of
40 minutes.
4.7. MALDI-TOF
For MALDI-TOF analysis sample solutions at a concentration
of 5 mg mL−1 at a 1 : 1 : 1 ratio with dithranol (40 mg mL−1,
THF) and sodium trifluoroacetate (10 mg mL−1, THF) as
matrix were employed. Linear positive mode was used on a
Bruker Ultraflex MALDI-TOF/TOF mass spectrometer with an
acceleration voltage of 25 kV.
4.8. Stability of PEG–haloperidol under physiological
conditions
Stability studies of PEG–haloperidol were carried out in rat
plasma. Briefly, 22 µL of either free haloperidol or PEG–halo-
peridol conjugate solution was added to 200 µL of rat plasma,
before vortexing for 1 min to ensure complete mixing.
200 µl of rat plasma was aliquoted out, and to this 22 µl, of
either, free haloperidol or PEG–haloperidol conjugate, solution
was added. This was vortexed for 1 min to ensure complete
mixing.
Mixtures were then divided into five equal aliquots for
analysis via HPLC at 0 h, 48 h, 24 h, 72 h and 168 h. The samples
were incubated at 37 °C to mimic physiological temperatures.
At the appropriate time point samples were removed from
incubation and quenched with 160 µl of, 1 : 1, acetonitrile :
methanol. This was then vortexed for 1 min, followed by cen-
trifugation at 3500 rpm for 2 min. This supernatant was
removed and filtered through a 0.45 µm syringe filter. The fil-
tered supernatant was then analysed via HPLC, using the
elution programme outlined in section 4.6.
4.9. Radioligand binding studies
Cell membranes (25 μg), of cells from CHO expressing the D2
receptor, were incubated with [3H]spiperone (0.25 nM) and
competing drugs in HEPES buﬀer (20 mM HEPES, 1 mM
EGTA, 1 mM EDTA, 10 mM MgCl2, pH 7.4 (using HCl) con-
taining 0.1 mM dithiothreitol) in a final volume of 1 ml for
3 h at 25 °C. The assay was terminated by rapid filtration
(through Whatman GF/C filters) using a Brandel cell har-
vester, followed by four washes with 4 ml ice-cold phosphate-
buﬀered saline (0.14 M NaCl, 3 mM KCl, 1.5 mM KH2PO4,
5 mM Na2HPO4; pH 7.4) to remove unbound radioactivity.
Filters were soaked in 2 ml of scintillation fluid for at least
5 h and bound radioactivity was determined by liquid scintil-
lation counting. Non-specific binding of [3H] spiperone was
determined in the presence of 3 μM (+)-butaclamol. The
data was analysed using GraphPad Prism software, version
5.04 and fitted to equations describing a one-site binding
model. pKi values for the data were obtained from non-linear
regression.
4.10. Theoretical modelling to assess the ability of PEG
conjugation to restrict passage haloperidol across the BBB
The following equation proposed by Fu et al.36 was used to
predict the BBB penetration of the free ligands and PEG-ligand
conjugates.
log BB ¼ " 9:880# 10"6Mw2 þ 7:339# 10"3Mw
" 0:2268npol " 0:1143 ð1Þ
The components of the model are defined as follows:
log BB = logarithm of the ratio of the steady state concentration
of the compound in the brain to the concentration of com-
pound in the blood, Mw = molecular weight, npol = the number
of polar atoms (oxygen, nitrogen and attached hydrogen).
The model was developed using 86 compounds, of which
8 were removed as outliers. The correlation coeﬃcient for the
78 remaining compounds was, r2 = 0.74.36
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